Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction

被引:0
|
作者
Palazzuoli, Alberto [1 ]
Severino, Paolo [2 ]
D'Amato, Andrea [2 ]
Myftari, Vincenzo [2 ]
Tricarico, Lucia [3 ]
Correale, Michele [3 ]
Dattilo, Giuseppe [4 ]
Fioretti, Francesco [5 ,6 ]
Nodari, Savina [5 ,6 ]
机构
[1] Le Scotte Hosp Univ Siena, Cardio Thorac & Vasc Dept, Cardiovasc Dis Unit, I-53100 Siena, Italy
[2] Univ Roma La Sapienza, Dept Clin Internal Anesthesiol & Cardiovasc Sci, I-00161 Rome, Italy
[3] UO Cardiol Univ, Intens Coronary Unit Policlin Riuniti Foggia, I-71122 Foggia, Italy
[4] Univ Hosp Messina, Dept Clin & Expt Med, Cardiol Unit, I-98122 Messina, Italy
[5] Spedali Civili Hosp, Dept Med & Surg Specialties, Cardiol Sect, Radiol Sci & Publ Hlth, I-25123 Brescia, Italy
[6] Univ Brescia, I-25123 Brescia, Italy
关键词
HFpEF phenotype; treatment; SGLT2i; ARNIs; MRA; GLP-1; QUALITY-OF-LIFE; RECEPTOR ANTAGONIST FINERENONE; COTRANSPORTER; INHIBITORS; OPEN-LABEL; CARDIOVASCULAR-DISEASE; PRESPECIFIED ANALYSIS; ATRIAL-FIBRILLATION; PEPTIDE-1; RECEPTOR; DIASTOLIC FUNCTION; EXERCISE CAPACITY;
D O I
10.31083/j.rcm2507270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Heart failure with preserved ejection fraction (HFpEF) is a multifactorial condition with a variety of pathophysiological causes and morphological manifestations. The inclusion criteria and patient classification have become overly simplistic due to the customary differentiation regarding the ejection fraction (EF) cutoff. EF is considered a measure of systolic function; nevertheless, it only represents a portion of the true contractile state and has been shown to have certain limits due to methodological and hemodynamic irregularities. Methods: As a result, broader randomized clinical trials have yet to incorporate the most recent criteria for HFpEF diagnosis, leading to a lack of data consistency and confusion in interpreting the results. The primary variations between the bigger clinical trials published in this context concerning patient selection and echocardiographic characteristics were analyzed. For all these reasons, we aim to clarify the main features and clinical impact of HFpEF in a study combining imaging, bio-humoral analysis, and clinical history to identify the specific subgroups that respond better to tailored treatment. Results: Disparate clinical characteristics and a lack of uniform diagnostic standards may cause suboptimal therapeutic feedback. To optimize treatment, we suggest shifting the paradigm from the straightforward EF measurement to a more comprehensive model that considers additional information, such as structural traits, related disorders, and biological and environmental data. Therefore, by evaluating certain echocardiographic and clinical factors, a stepwise diagnostic procedure may be useful in identifying patients at high risk, subjects with early HFpEF, and those with evident HFpEF. Conclusions: The present assessment underscores the significance of the precision medicine approach in guaranteeing optimal patient outcomes by providing the best care according to each distinct profile.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Targets for Heart Failure With Preserved Ejection Fraction
    Nanayakkara, S.
    Kaye, D. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (02) : 228 - 237
  • [2] In Search of New Targets and Endpoints in Heart Failure With Preserved Ejection Fraction
    Borlaug, Barry A.
    [J]. JACC-HEART FAILURE, 2015, 3 (06) : 475 - 477
  • [3] Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction
    Yamamoto, Kazuhiro
    [J]. YONAGO ACTA MEDICA, 2017, 60 (02) : 71 - 76
  • [4] Heart failure with preserved ejection fraction:A distinct heart failure phenotype?
    Filippos Triposkiadis
    Grigorios Giamouzis
    John Skoularigis
    Andrew Xanthopoulos
    [J]. World Journal of Clinical Cases, 2022, 10 (32) : 12052 - 12055
  • [5] Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
    Triposkiadis, Filippos
    Giamouzis, Grigorios
    Skoularigis, John
    Xanthopoulos, Andrew
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (32) : 12052 - 12055
  • [6] Heart failure with preserved ejection fraction: A precursor of heart failure with reduced ejection fraction or a distinct syndrome?
    Miani, Daniela
    Badano, Luigi P.
    De Biaggio, Paola
    Albanese, Maria Cecilia
    Ghidina, Marco
    Proclemer, Alessandro
    Fioretti, Paolo
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 149 (01) : 139 - 140
  • [7] HEART FAILURE WITH RECOVERED EJECTION FRACTION: A DISTINCT ENTITY WITHIN HEART FAILURE AND PRESERVED EJECTION FRACTION
    Punnoose, Lynn
    Pratibhu, Parakash
    Givertz, Michael M.
    Lewis, Eldrin F.
    Stevenson, Lynne W.
    Desai, Akshay
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [8] Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction
    Paulus, Walter J.
    Dal Canto, Elisa
    [J]. JACC-HEART FAILURE, 2018, 6 (01) : 1 - 7
  • [9] Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets
    Borlaug, Barry A.
    Jensen, Michael D.
    Kitzman, Dalane W.
    Lam, Carolyn S. P.
    Obokata, Masaru
    Rider, Oliver J.
    [J]. CARDIOVASCULAR RESEARCH, 2023, 118 (18) : 3434 - 3450
  • [10] Pressure-volume Profiles In Heart Failure With Reduced Ejection Fraction And Heart Failure With Preserved Ejection Fraction
    Kittipibul, Veraprapas
    Yaranov, Dmitry
    Rao, Vishal
    Jefferies, John
    Silver, Marc A.
    Fudim, Marat
    [J]. JOURNAL OF CARDIAC FAILURE, 2023, 29 (04) : 603 - 603